Follow the dose and duration on your prescription and do not change it on your own
MEM, Meropenem
CagriSema CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-administered once weekly and studied in Phase 3 trials for obesity and type 2 diabetes.
Small NADs, such as siRNA, and large ones, such as mRNA, in addition to the necessary modifications, still require the aid of delivery vectors
Shortened telomeres are associated with cellular aging, and compounds that influence this pathway are of growing interest in longevity medicine
On the other hand, in the Si-DSS group, only a few macrophages were observed in the submucosa of the rectum on the 3rd day after DSS treatment, and almost no macrophages were observed in the colon (Fig